Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec(r))

MLA

“Breckenridge Announces Final Approval of Its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec(R)).” Plus Company Updates, 5 Mar. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.577155808&authtype=sso&custid=ns315887.

APA

Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec(r)). (2019, March 5). Plus Company Updates.

Chicago

Plus Company Updates. 2019. “Breckenridge Announces Final Approval of Its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec(R)),” March 5. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.577155808&authtype=sso&custid=ns315887.